Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma.
Radiotherapy is the first-line treatment for all stages of cervical cancer, whether it is used for radical or palliative therapy. However, radioresistance of cervical cancer remains a major therapeutic problem. Consequently, we explored if E-cadherin (a marker of epithelial-mesenchymal transition) and osteopontin could predict radioresistance in patients with locally advanced cervical squamous cell carcinoma (LACSCC). Patients were retrospectively reviewed and 111 patients divided into two groups (radiation-resistant and radiation-sensitive groups) according to progression-free survival (PFS). In pretreated paraffin-embedded tissues, we evaluated E-cadherin and osteopontin expression using immunohistochemical staining. The percentage of patients with high osteopontin but low E-cadherin expression in the radiation-resistant group was significantly higher than those in the radiation-sensitive group (p<0.001). These patients also had a lower 5-year PFS rate (p<0.001). Our research suggests that high osteopontin but low E-cadherin expression can be considered as a negative, independent prognostic factor in patients with LACSCC ([Hazard ratios (95% CI) 6.766 (2.940, 15.572)], p<0.001).
Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (LS, XH, YQ, QZ, YW, WK, KL)
Xinqiong
X
Huang
Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (LS, XH, YQ, QZ, YW, WK, KL)
Yujie
Y
Qian
Department of Clinical Medicine, the NCO School of the Border Control Force Yunnan Province, P.R. China (HW)
Hainan
H
Wu
Department of Radiation Oncology, Hunan Provincial Tumal Hospital & Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Hunan Province, P.R. China (XX)
Xiaoxue
X
Xie
Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (LS, XH, YQ, QZ, YW, WK, KL)
Qin
Q
Zhou
Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (LS, XH, YQ, QZ, YW, WK, KL)
Ying
Y
Wang
Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (LS, XH, YQ, QZ, YW, WK, KL)
Weilu
W
Kuang
Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (LS, XH, YQ, QZ, YW, WK, KL)|Xiangya of medicine, Central South University, Hunan Province, P.R. China (LS)
Lin
L
Shen
Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (LS, XH, YQ, QZ, YW, WK, KL)
Kai
K
Li
Department of Dermatology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (XC, JS)
Juan
J
Su
Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (LS, XH, YQ, QZ, YW, WK, KL)|Xiangya of medicine, Central South University, Hunan Province, P.R. China (LS)
Liangfang
L
Shen
Department of Dermatology, Xiangya Hospital, Central South University, Hunan Province, P.R. China (XC, JS)
Xiang
X
Chen
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000528:radiation effects; D006801:Humans; D008875:Middle Aged; D053495:Osteopontin / Q000378:metabolism*; D011836:Radiation Tolerance; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy
D014408:Biomarkers, Tumor; D015820:Cadherins; D053495:Osteopontin
E-cadherin; epithelial-mesenchymal transition; immunohistochemistry; locally advanced cervical squamous cell carcinoma; osteopontin; radiation resistance